Trade

with

Transcept Pharmaceuticals Inc
(NASDAQ: TSPT)
AdChoices
1.80
-0.12
-6.25%
After Hours :
-
-
-

Open

1.86

Previous Close

1.92

Volume (Avg)

37.68k (68.24k)

Day's Range

1.80-1.99

52Wk Range

1.80-3.90

Market Cap.

34.49M

Dividend Rate ( Yield )

-

Beta

0.86

Shares Outstanding

19.16M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Biotechnology
Highlights
Analyst Recommendation: Not Available
    • Revenue

    • 1.75M

    • Net Income

    • -27.45M

    • Market Cap.

    • 34.49M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -1,046.55

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 0.86

    • Forward P/E

    • -

    • Price/Sales

    • 21.69

    • Price/Book Value

    • 0.82

    • Price/Cash flow

    • -4.42

      • EBITDA

      • -27.28M

      • Return on Capital %

      • -26.05

      • Return on Equity %

      • -26.88

      • Return on Assets %

      • -26.05

      • Book Value/Share

      • 2.19

      • Shares Outstanding

      • 19.16M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      -
      Not Available
        • 1 Year Price Target

        • -

        • Credit Rating

        • -

        • Analysts

        • 0

        • EPS Estimate

        • -

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • -24.70

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • -50.80

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • -336.13

            • 82.75

            • Pre-Tax Margin

            • -1,046.55

            • 39.38

            • Net Profit Margin

            • -1,046.55

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • 19.30

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -438.50

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.76

              • Current Ratio

              • 17.79

              • 2.92

              • Quick Ratio

              • 17.42

              • 2.35

              • Interest Coverage

              • -

              • 38.02

              • Leverage Ratio

              • 1.06

              • 2.21

              • Book Value/Share

              • 2.19

              • 4.79

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -2.44

                • 243.90

                • P/E Ratio 5-Year High

                • -16.99

                • 634.30

                • P/E Ratio 5-Year Low

                • -2.07

                • 124.82

                • Price/Sales Ratio

                • 25.58

                • 9.29

                • Price/Book Value

                • 0.97

                • 8.39

                • Price/Cash Flow Ratio

                • -4.42

                • 49.75

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -26.88

                    (-19.10)

                  • 37.63

                    (27.20)

                  • Return on Assets %

                    (5-Year Average)

                  • -26.05

                    (-17.30)

                  • 17.22

                    (13.81)

                  • Return on Capital %

                    (5-Year Average)

                  • -26.88

                    (-19.00)

                  • 21.78

                    (17.31)

                  • Income/Employee

                  • -

                  • 117.08k

                  • Inventory Turnover

                  • -

                  • 1.48

                  • Asset Turnover

                  • 0.02

                  • 0.55

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -27.37M
                  Operating Margin
                  -1,566.74
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -4.42
                  Ownership

                  Institutional Ownership

                  61.60%

                  Top 10 Institutions

                  56.25%

                  Mutual Fund Ownership

                  9.56%

                  Float

                  62.76%

                  5% / Insider Ownership

                  5.27%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Roumell Opportunistic Value Fund

                  •  

                    498,550

                  • 0.00

                  • 2.60

                  • Vanguard Total Stock Mkt Idx

                  •  

                    253,476

                  • 0.00

                  • 1.32

                  • Vanguard Extended Market Index Fund

                  •  

                    137,442

                  • 0.00

                  • 0.72

                  • Franklin Biotechnology Discovery

                  •  

                    129,819

                  • 0.00

                  • 0.69

                  • AQR Diversified Arbitrage Fund

                  •  

                    122,838

                  • 0.00

                  • 0.65

                  • DFA U.S. Micro Cap Portfolio

                  •  

                    111,214

                  • 0.00

                  • 0.59

                  • DFA U.S. Small Cap Portfolio

                  •  

                    73,786

                  • 0.00

                  • 0.39

                  • Bridgeway Ultra Small Company Fund

                  •  

                    70,000

                  • 0.00

                  • 0.37

                  • Bridgeway Ultra Small Company Market

                  •  

                    65,000

                  • 0.00

                  • 0.34

                  • DFA US Targeted Value Portfolio

                  •  

                    61,189

                  • 0.00

                  • 0.32

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • NEA Management Company, LLC

                  •  

                    2,086,755

                  • 0.00%

                  • 11.07

                  • InterWest Partners

                  •  

                    1,983,884

                  • 0.00%

                  • 10.52

                  • Roumell Asset Management, LLC

                  •  

                    1,942,184

                  • -4.41%

                  • 10.30

                  • SC Fundamental LLC

                  •  

                    1,265,365

                  • 0.00%

                  • 6.72

                  • Dimensional Fund Advisors, Inc.

                  •  

                    466,573

                  • -0.87%

                  • 2.47

                  • Vanguard Group, Inc.

                  •  

                    327,417

                  • +8.81%

                  • 1.74

                  • Renaissance Technologies Corp

                  •  

                    227,846

                  • +156.01%

                  • 1.21

                  • AQR Capital Management LLC

                  •  

                    209,318

                  • 0.00%

                  • 1.11

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Biotechnology

                  Type

                  Distressed

                  Style

                  Small Value

                  Transcept Pharmaceuticals, Inc. was incorporated in Delaware in February 2001. It is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs...more in the field of neuroscience. Intermezzo or zolpidem tartrate sublingual tablet C-IV is the first FDA approved Transcept product. Purdue holds commercialization and development rights for Intermezzo in the United States. Transcept is currently conducting a Phase 2 study of an investigational product, TO-2061, in patients with obsessive-compulsive disorder. The Company competes with Ambien and Ambien CR marketed by sanofi-aventis, Lunesta marketed by Sunovion Pharmaceuticals Inc., Rozerem marketed by Takeda Pharmaceuticals Company Limited, Sonata marketed by King Pharmac...moreeuticals, Inc. and generic forms of this product, Silenor, a product developed by Somaxon Pharmaceuticals, Inc., and a number of other pharmaceutical agents. The Company is subject to the government regulations of the state and country.lessless

                  Key People

                  Glenn A. Oclassen

                  CEO/Chairman of the Board/Director/President

                  Ms. Leone Patterson

                  CFO/Chief Accounting Officer/Vice President

                  Matthew M. Loar

                  Director

                  Jake R. Nunn

                  Director

                  G. Kirk Raab

                  Director

                  • Transcept Pharmaceuticals Inc

                  • 1003 W. Cutting Blvd

                  • Point Richmond, CA 94804

                  • USA.Map

                  • Phone: +1 510 215-3500

                  • Fax: +1 510 215-3535

                  • transcept.com

                  Incorporated

                  2001

                  Employees

                  8

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: